Thamer, Claus

Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms

Schäfer, S. A., Tschritter, O., Machicao, F., Thamer, C., Stefan, N., Gallwitz, B., Holst, J. J., Dekker, J. M., t’Hart, L. M., Nijpels, G., et al. (2007) · Diabetologia

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 308

High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease

Kantartzis, K., Thamer, C., Peter, A., Machann, J., Schick, F., Schraml, C., Konigsrainer, A., Konigsrainer, I., Krober, S., Niess, A., et al. (2009) · Gut

Liver Disease Diagnosis and TreatmentPhysical Activity and Health

Cited by 273

Intermuscular adipose tissue (IMAT): Association with other adipose tissue compartments and insulin sensitivity

Boettcher, M., Machann, J., Stefan, N., Thamer, C., Häring, H., Claussen, C. D., Fritsche, A., & Schick, F. (2009) · Journal of Magnetic Resonance Imaging

Cardiovascular Disease and AdiposityAdipokines, Inflammation, and Metabolic Diseases

Cited by 214

Hepatic lipid accumulation in healthy subjects: A comparative study using spectral fat‐selective MRI and volume‐localized 1H‐MR spectroscopy

Machann, J., Thamer, C., Schnoedt, B., Stefan, N., Haring, H., Claussen, C. D., Fritsche, A., & Schick, F. (2006) · Magnetic Resonance in Medicine

Advanced MRI Techniques and ApplicationsLiver Disease Diagnosis and Treatment

Cited by 162

Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids

Thamer, C., Tschritter, O., Haap, M., Shirkavand, F., Machann, J., Fritsche, A., Schick, F., Häring, H., & Stumvoll, M. (2005) · Hormone and Metabolic Research

Diabetes, Cardiovascular Risks, and LipoproteinsLiver Disease Diagnosis and Treatment

Cited by 119

Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906

Jungnik, A., Arrubla Martinez, J., Plum‐Mörschel, L., Kapitza, C., Lamers, D., Thamer, C., Schölch, C., Desch, M., & Hennige, A. M. (2023) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 63